# US 2022/0034871 A1 · Methods for administering pexidartinib

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0034871 A1
- Document ID: US20220034871A1
- Status: Published application
- Kind: A1
- Application number: 17/390,193
- Filed: 2021-07-30
- Published: 2022-02-03
- Earliest claimed: 2020-07-31
- Assignees: Daiichi Sankyo Company, Limited
- Applicants: Daiichi Sankyo Company, Limited
- Inventors: Dale Edward SHUSTER; Hamim ZAHIR; Ophelia Qiping YIN; Leonidas Daniel DROGARIS; Vikram Jeet DEV; Laurie DELEVE; James Hendricks LEWIS
- Web page: https://patentgrep.com/patent/US20220034871A1

## CPC

- G01N 33/5067: {Liver cells}
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 10/60: for patient-specific data, e.g. for electronic patient records
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G01N 33/728: {Bilirubin; including biliverdin}
- G01N 2333/9108: with definite EC number (2.3.2.-)
- G01N 2333/91188: transferring nitrogenous groups (2.6)
- G01N 2333/916: acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N 2800/085: Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present disclosure relates generally to methods for using pexidartinib and related Risk Evaluation and Mitigation Strategy (REMS), while reducing the occurrence of hepatotoxic adverse events.

## Claims

### Claim 1

A method of administering pexidartinib, or a pharmaceutically acceptable salt thereof, to a patient while avoiding serious and potentially fatal liver injury, the method comprising:
a) administering to the patient a dose of 400 mg equivalent of pexidartinib twice daily;
b) monitoring the patient by measuring the patient's liver function; and
c) reducing the dose or permanently discontinuing administration based on the patient's liver function.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient is being treated for symptomatic tenosynovial giant cell tumor (TGCT).

### Claim 3 (depends on 1)

The method of claim 1, wherein the measuring of the patient's liver function comprises measuring levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin (TB) and direct bilirubin (DB) or a combination thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein if the ALT or AST level is greater than 3 to 5 times the corresponding upper limit of normal (ULN), then the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is
withheld and the liver function measurements are conducted weekly; and
i) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
ii) if the AST or ALT level is not less than or equal to 3 times the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 5 (depends on 3)

The method of claim 3, wherein if the ALT or AST level is greater than 5 to 10 times the corresponding upper limit of normal (ULN), then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted twice a week; and
a) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the AST or ALT level is not less than or equal to 3 times the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 6 (depends on 3)

The method of claim 3, wherein if the ALT or AST level is greater than 10 times the corresponding upper limit of normal (ULN), then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the AST or ALT levels are less than or equal to 5 times the corresponding ULN, and then
the liver function measurements are conducted weekly until the AST or ALT levels are less than or equal to 3 times the corresponding ULN.

### Claim 7 (depends on 3)

The method of claim 3, wherein if the ALP level is greater than 2 times the corresponding ULN and the GGT is greater than 2 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the ALP level is less than or equal to 5 times the corresponding ULN, and then
the liver function measurements are conducted weekly until the ALP level is less than or equal to 2 times the corresponding ULN.

### Claim 8 (depends on 1)

The method of claim 1, wherein the measuring of the patient's liver function comprises measuring levels of total bilirubin (TB), direct bilirubin (DB), or a combination thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein if the TB level is greater than the corresponding ULN and less than 2 times the corresponding ULN or the DB level is greater than the corresponding ULN and less than 1.5 times the corresponding ULN, then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted twice a week; and
a) if an alternate cause for the increased bilirubin is confirmed and the TB or DB level is less than the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the TB or DB level is not less than corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 10 (depends on 8)

The method of claim 8, wherein if the TB level is greater than or equal to 2 times the corresponding ULN or the DB level is greater than 1.5 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the TB or DB level is less than or equal to the corresponding ULN.

### Claim 11 (depends on 1)

The method of claim 1, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a cytochrome P450 3A (CYP3A) inhibitor, a uridine diphosphate-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose if co-administered with a CYP3A inhibitor, a UDP-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a proton pump inhibitor.

### Claim 14 (depends on 1)

The method of claim 1, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose in the patient, wherein the patient has mild to severe renal impairment as defined by creatinine clearance [CLcr] 15 to 89 mL/min estimated by Cockcroft-Gault using actual body weight.

### Claim 15 (depends on 4)

The method of claim 4, wherein a reduced dose of pexidartinib, or a pharmaceutically acceptable salt thereof, is a change in dose from 800 mg equivalent of pexidartinib daily to 600 mg equivalent of pexidartinib daily or 400 mg equivalent of pexidartinib daily.

### Claim 16

A method for administering pexidartinib, or a pharmaceutically acceptable salt thereof, to a patient while minimizing a risk of serious and potentially fatal liver injury, the method comprising:
a) registering one or more healthcare providers in a healthcare provider database in a non-transitory computer readable storage medium, wherein the one or more healthcare providers have completed a knowledge assessment regarding pexidartinib;
b) requiring the one or more healthcare providers to assess the patient's baseline liver functions;
c) registering the patient in a database, wherein the patients has reviewed a patient guide and has had a baseline liver function assessed; and
d) during treatment, re-assessing the patient's liver functions and modifying a dose of pexidartinib, or a pharmaceutically acceptable salt thereof, as needed.

### Claim 17 (depends on 16)

The method of claim 16, further comprising registering one or more pharmacies which have completed a certification program regarding pexidartinib, or a pharmaceutically acceptable salt thereof, in a pharmacy database, and wherein the one or more pharmacies only dispense pexidartinib, or a pharmaceutically acceptable salt thereof, to patients who are registered in the patient database.

### Claim 18 (depends on 16)

The method of claim 16, wherein the assessing of the patient's baseline liver function comprises measuring levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin (TB) and direct bilirubin (DB) or a combination thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein if the ALT or AST level is greater than 3 to 5 times the corresponding upper limit of normal (ULN), then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted weekly; and
a) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the AST or ALT level is not less than or equal to 3 times the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 20 (depends on 18)

The method of claim 18, wherein if the ALT or AST level is greater than 5 to 10 times the corresponding upper limit of normal (ULN), then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted twice a week; and
a) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the AST or ALT level is not less than or equal to 3 times ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 21 (depends on 18)

The method of claim 18, wherein if the ALT or AST level is greater than 10 times the corresponding upper limit of normal (ULN), then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the AST or ALT levels are less than or equal to 5 times the corresponding ULN, and then
the liver function measurements are conducted weekly until the AST or ALT levels are less than or equal to 3 times the corresponding ULN.

### Claim 22 (depends on 18)

The method of claim 18, wherein if the ALP level is greater than 2 times the corresponding ULN with the GGT greater than 2 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until ALP level is less than or equal to 5 times the corresponding ULN and then
the liver function measurements are conducted weekly until ALP level is are less than or equal to 2 times the corresponding ULN.

### Claim 23 (depends on 16)

The method of claim 16, wherein the assessing of the patient's liver function comprises measuring levels of total bilirubin (TB), direct bilirubin (DB), or a combination thereof.

### Claim 24 (depends on 23)

The method of claim 23, wherein if TB is greater than the corresponding ULN to less than 2 times the corresponding ULN or DB is greater than the corresponding ULN and less than 1.5 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and liver function measurements are conducted twice a week; and
b) if an alternate cause for the increased bilirubin is confirmed and the TB or DB level is less than the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
c) if the TB or DB level is not less than the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 25 (depends on 23)

The method of claim 23, wherein if the TB level is greater or equal to 2 times the corresponding ULN or DB is greater than 1.5 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the TB or DB levels is less than or equal to the corresponding ULN.

### Claim 26 (depends on 16)

The method of claim 16, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a CYP3A inhibitor, a UDP-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 27 (depends on 16)

The method of claim 16, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose if co-administered with a CYP3A inhibitor, a UDP-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 28 (depends on 16)

The method of claim 16, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a proton pump inhibitor.

### Claim 29 (depends on 16)

The method of claim 16, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose in the patient, wherein the patient has mild to severe renal impairment as defined by creatinine clearance [CLcr] 15 to 89 mL/min estimated by Cockcroft-Gault using actual body weight.

### Claim 30 (depends on 19)

The method of claim 19, wherein a reduced dose of pexidartinib, or a pharmaceutically acceptable salt thereof, is a change in dose from 800 mg equivalent of pexidartinib daily to 600 mg equivalent of pexidartinib daily or 400 mg equivalent of pexidartinib daily.

### Claim 31

A method of treating a patient with pexidartinib, or a pharmaceutically acceptable salt thereof, while avoiding serious and potentially fatal liver injury, wherein the patient having symptomatic tenosynovial giant cell tumor (TGCT), the method comprising:
a) administering to the patient a dose of 400 mg equivalent of pexidartinib twice daily;
b) monitoring the patient by measuring the patient's liver function; and
c) reducing the dose or permanently discontinuing administration based on the patient's liver function.

### Claim 32 (depends on 31)

The method of claim 31, wherein the measuring of the patient's liver function comprises measuring levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin (TB) and direct bilirubin (DB) or a combination thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein if the ALT or AST level is greater than 3 to 5 times the corresponding upper limit of normal (ULN), then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted weekly; and
i) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
ii) if the AST or ALT level is not less than or equal to 3 times the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 34 (depends on 32)

The method of claim 32, wherein if the ALT or AST level is greater than 5 to 10 times the corresponding upper limit of normal (ULN), then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted twice a week; and
a) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the AST or ALT level is not less than or equal to 3 times the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 35 (depends on 32)

The method of claim 32, wherein if the ALT or AST level is greater than 10 times the corresponding upper limit of normal (ULN), then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the AST or ALT levels are less than or equal to 5 times the corresponding ULN, and then
the liver function measurements are conducted weekly until the AST or ALT levels are less than or equal to 3 times the corresponding ULN.

### Claim 36 (depends on 32)

The method of claim 32, wherein if the ALP level is greater than 2 times the corresponding ULN and the GGT is greater than 2 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the ALP level is less than or equal to 5 times the corresponding ULN, and then
the liver function measurements are conducted weekly until the ALP level is are less than or equal to 2 times the corresponding ULN.

### Claim 37 (depends on 31)

The method of claim 31, wherein the measuring the patient's liver function comprises measuring levels of total bilirubin (TB), direct bilirubin (DB), or a combination thereof.

### Claim 38 (depends on 37)

The method of claim 37, wherein if the TB level is greater than the corresponding ULN and less than 2 times the corresponding ULN or the DB level is greater than the corresponding ULN and less than 1.5 times the corresponding ULN, then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted twice a week; and
a) if an alternate cause for the increased bilirubin is confirmed and the TB or DB level is less than the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the TB or DB level is not less than corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 39 (depends on 37)

The method of claim 37, wherein if the TB level is greater than or equal to 2 times the corresponding ULN or the DB level is greater than 1.5 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the TB or DB level is less than or equal to the corresponding ULN.

### Claim 40 (depends on 31)

The method of claim 31, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a cytochrome P450 3A (CYP3A) inhibitor, a uridine diphosphate-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 41 (depends on 31)

The method of claim 31, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose if co-administered with a CYP3A inhibitor, a UDP-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 42 (depends on 31)

The method of claim 31, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a proton pump inhibitor.

### Claim 43 (depends on 31)

The method of claim 31, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose in a patient, wherein the patient has mild to severe renal impairment as defined by creatinine clearance [CLcr] 15 to 89 mL/min estimated by Cockcroft-Gault using actual body weight.

### Claim 44 (depends on 33)

The method of claim 33, wherein a reduced dose of pexidartinib, or a pharmaceutically acceptable salt thereof, is a change in dose from 800 mg equivalent of pexidartinib daily to 600 mg equivalent of pexidartinib daily or 400 mg equivalent of pexidartinib daily.

### Claim 45

A method for treating a patient with pexidartinib, or a pharmaceutically acceptable salt thereof, while minimizing a risk of serious and potentially fatal liver injury, wherein the patient having symptomatic tenosynovial giant cell tumor (TGCT), the method comprising:
a) administering to the patient a dose of 400 mg equivalent of pexidartinib twice daily;
b) registering one or more healthcare providers in a healthcare provider database in a non-transitory computer readable storage medium, wherein the one or more healthcare providers have completed a knowledge assessment regarding pexidartinib;
c) requiring the one or more healthcare providers to assess the patient's baseline liver functions;
d) registering the patient in a database, wherein the patient has reviewed a patient guide and has had a baseline liver function assessed; and
e) during treatment, re-assessing a patient's liver function and reducing the dose or permanently discontinuing administration based on the patient's liver function.

### Claim 46 (depends on 45)

The method of claim 45, further comprising registering one or more pharmacies which have completed a certification program regarding pexidartinib, or a pharmaceutically acceptable salt thereof, in a pharmacy database, and wherein the pharmacies only dispense pexidartinib, or a pharmaceutically acceptable salt thereof, to patients who are registered in the patient database.

### Claim 47 (depends on 45)

The method of claim 45, wherein the assessing of the patient's baseline liver function comprises measuring levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin (TB) and direct bilirubin (DB) or a combination thereof.

### Claim 48 (depends on 47)

The method of claim 47, wherein if the ALT or AST level is greater than 3 to 5 times the corresponding upper limit of normal (ULN), then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted weekly; and
a) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the AST or ALT level is not less than or equal to 3 times the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 49 (depends on 47)

The method of claim 47, wherein if the ALT or AST level is greater than 5 to 10 times the corresponding upper limit of normal (ULN), then
the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and the liver function measurements are conducted twice a week; and
a) if the AST and ALT levels are less than or equal to 3 times the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
b) if the AST or ALT level is not less than or equal to 3 times ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 50 (depends on 47)

The method of claim 47, wherein if the ALT or AST level is greater than 10 times the corresponding upper limit of normal (ULN), then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the AST or ALT levels are less than or equal to 5 times the corresponding ULN, and then
the liver function measurements are conducted weekly until the AST or ALT levels are less than or equal to 3 times the corresponding ULN.

### Claim 51 (depends on 47)

The method of claim 47, wherein if the ALP level is greater than 2 times the corresponding ULN with the GGT greater than 2 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until ALP level is less than or equal to 5 times the corresponding ULN, and then
the liver function measurements are conducted weekly until ALP level is are less than or equal to 2 times the corresponding ULN.

### Claim 52 (depends on 45)

The method of claim 45, wherein the assessing of the patient's liver function comprises measuring levels of total bilirubin (TB), direct bilirubin (DB), or a combination thereof.

### Claim 53 (depends on 52)

The method of claim 52, wherein if TB is greater than the corresponding ULN to less than 2 times the corresponding ULN or DB is greater than the corresponding ULN and less than 1.5 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is withheld and liver function measurements are conducted twice a week; and
b) if an alternate cause for the increased bilirubin is confirmed and the TB or DB level is less than the corresponding ULN within 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is resumed at a reduced dose; or
c) if the TB or DB level is not less than the corresponding ULN in 4 weeks, the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued.

### Claim 54 (depends on 52)

The method of claim 52, wherein if the TB level is greater or equal to 2 times the corresponding ULN or DB is greater than 1.5 times the corresponding ULN, then
a) the administration of pexidartinib, or a pharmaceutically acceptable salt thereof, is permanently discontinued; and
b) the liver function measurements are conducted twice a week until the TB or DB levels is less than or equal to the corresponding ULN.

### Claim 55 (depends on 45)

The method of claim 45, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a CYP3A inhibitor, a UDP-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 56 (depends on 45)

The method of claim 45, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose if co-administered with a CYP3A inhibitor, a UDP-glucuronosyltransferase (UGT) inhibitor, or a combination thereof.

### Claim 57 (depends on 45)

The method of claim 45, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is not co-administered with a proton pump inhibitor.

### Claim 58 (depends on 45)

The method of claim 45, wherein pexidartinib, or a pharmaceutically acceptable salt thereof, is administered at a reduced dose in the patient, wherein the patient has mild to severe renal impairment as defined by creatinine clearance [CLcr] 15 to 89 mL/min estimated by Cockcroft-Gault using actual body weight.

### Claim 59 (depends on 48)

The method of claim 48, wherein a reduced dose of pexidartinib, or a pharmaceutically acceptable salt thereof, is a change in dose from 800 mg equivalent of pexidartinib daily to 600 mg equivalent of pexidartinib daily or 400 mg equivalent of pexidartinib daily.
